Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients
Authors:
- Giovanni AnnuzziGAGiovanni Annuzzi
- Fabiana PiscitelliFabiana Piscitelli
- Lucrezia Di MarinoLMLucrezia Di Marino
- Lidia PattiLPLidia Patti
- Rosalba GiaccoRGRosalba Giacco
- Giuseppina CostabileGCGiuseppina Costabile
- Lutgarda BozzettoLBLutgarda Bozzetto
- Gabriele RiccardiGRGabriele Riccardi
- Roberta VerdeRVRoberta Verde
- Stefania PetrosinoSPStefania Petrosino
- Angela A RivelleseARAngela A Rivellese
- Vincenzo Di MarzoVincenzo Di Marzo
Open Access
- 28 April 2010
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 9 (1) , 1-8
Abstract
Background: The endocannabinoids, anandamide and 2-AG, are produced by adipocytes, where they stimulate lipogenesis via cannabinoid CB1 receptors and are under the negative control of leptin and insulin. Endocannabinoid levels are elevated in the blood of obese individuals and nonobese type 2 diabetes patients. To date, no study has evaluated endocannabinoid levels in subcutaneous adipose tissue (SAT) of subjects with both obesity and type 2 diabetes (OBT2D), characterised by similar adiposity and whole body insulin resistance and lower plasma leptin levels as compared to non-diabetic obese subjects (OB). Design and Methods: The levels of anandamide and 2-AG, and of the anandamide-related PPARα ligands, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), in the SAT obtained by abdominal needle biopsy in 10 OBT2D, 11 OB, and 8 non-diabetic normal-weight (NW) subjects, were measured by liquid chromatography-mass spectrometry. All subjects underwent a hyperinsulinaemic euglycaemic clamp. Results: As compared to NW, anandamide, OEA and PEA levels in the SAT were 2-4.4-fold elevated (p < 0.05), and 2-AG levels 2.3-fold reduced (p < .05), in OBT2D but not in OB subjects. Anandamide, OEA and PEA correlated positively (p < .05) with SAT leptin mRNA and free fatty acid during hyperinsulinaemic clamp, and negatively with SAT LPL activity and plasma HDL-cholesterol, which were all specifically altered in OBT2D subjects. Conclusions: The observed alterations emphasize, for the first time in humans, the potential different role and regulation of adipose tissue anandamide (and its congeners) and 2-AG in obesity and type 2 diabetes.Keywords
This publication has 40 references indexed in Scilit:
- Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re‐feedingBritish Journal of Pharmacology, 2009
- Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistanceNutrition, Metabolism and Cardiovascular Diseases, 2008
- Low plasma leptin levels in well controlled type 2 diabetes are not related to body fat mass and whole-body insulin resistanceNutrition, Metabolism and Cardiovascular Diseases, 2008
- Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetesClinical Nutrition, 2008
- Immune-mediated Activation of the Endocannabinoid System in Visceral Adipose Tissue in ObesityHormone and Metabolic Research, 2007
- Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese menInternational Journal of Obesity, 2007
- Abdominal obesity and metabolic syndromeNature, 2006
- Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal ObesityDiabetes, 2006
- The dysregulated adipose tissue: A connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosisNutrition, Metabolism and Cardiovascular Diseases, 2006
- Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α)Journal of Biological Chemistry, 2004